West Pharmaceutical Services (WST) Stock Price, News & Analysis

Company Overview

West Pharmaceutical Services, Inc. (NYSE: WST) is a global manufacturer and supplier of innovative packaging and delivery systems for injectable drugs and healthcare products. The company designs, engineers and produces a broad range of components, including elastomeric closures, syringe plungers and containment solutions that ensure drug integrity throughout development, packaging and administration. By integrating precision polymer and rubber technologies, West enables pharmaceutical and biotechnology customers to deliver safe and effective therapies to patients worldwide.

The company’s product portfolio spans co-molded elastomer components, prefillable syringes, safety systems and specialty containment platforms. West offers end-to-end support services, from concept and design through to commercial tooling and global supply chain management. Its proprietary SmartDose® wearable injector and Flip-Off® seals are widely used in subcutaneous drug delivery, while the Daikyo Crystal Zenith® polymer containers provide high-chemical resistance and reduced risk of leachables.

Founded in 1923 and headquartered in Exton, Pennsylvania, West has grown through strategic acquisitions and organic investments to establish a strong global footprint. Manufacturing and technical centers are located across North America, Europe and the Asia-Pacific region, including sites in Puerto Rico, Ireland, Germany, China and Singapore. The company maintains rigorous quality standards and regulatory compliance, supporting both large pharmaceutical firms and emerging biotech innovators.

Under the leadership of President and Chief Executive Officer Cristian J. Goodman, West continues to emphasize research and development, operational excellence and sustainability. The executive team focuses on advancing drug delivery science and expanding the company’s capacity to address evolving patient needs. Through partnerships and ongoing product innovation, West Pharmaceutical Services remains at the forefront of injectable drug packaging and delivery solutions.

Key Stats

• Today's Range: $220.34 to $224.41
• 50-Day Range: $205.45 to $227.45
• 52-Week Range: $187.43 to $352.33
• Volume: 370,766 shs
• Average Volume: 735,377 shs
• Market Capitalization: $15.93 billion
• P/E Ratio: 34.81
• Dividend Yield: 0.38%
• Price Target: $320.00
• Consensus Rating: Moderate Buy

West Pharmaceutical Services Stock Analysis - MarketRank™

West Pharmaceutical Services scored higher than 95% of companies evaluated by MarketBeat, and ranked 58th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

West Pharmaceutical Services has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

West Pharmaceutical Services has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 18.73%

Earnings Growth

Earnings for West Pharmaceutical Services are expected to grow by 18.73% in the coming year, from $6.62 to $7.86 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of West Pharmaceutical Services is 34.81, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of West Pharmaceutical Services is 34.81, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.51.

Price to Earnings Growth Ratio

West Pharmaceutical Services has a PEG Ratio of 5.47. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

West Pharmaceutical Services has a P/B Ratio of 5.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.91% of the float of West Pharmaceutical Services has been sold short.

Short Interest Ratio / Days to Cover

West Pharmaceutical Services has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in West Pharmaceutical Services has recently decreased by 2.35%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

West Pharmaceutical Services has a dividend yield of 0.38%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

West Pharmaceutical Services does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of West Pharmaceutical Services is 13.19%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 10.69% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.2 / 5
• Environmental Score: -2.53

Percentage of Shares Shorted

2.91% of the float of West Pharmaceutical Services has been sold short.

Short Interest Ratio / Days to Cover

West Pharmaceutical Services has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in West Pharmaceutical Services has recently decreased by 2.35%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.32

News Sentiment

West Pharmaceutical Services has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 37 news articles for West Pharmaceutical Services this week, compared to 16 articles on an average week.

Search Interest

8 people have searched for WST on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, West Pharmaceutical Services insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.53% of the stock of West Pharmaceutical Services is held by insiders.

Percentage Held by Institutions

93.90% of the stock of West Pharmaceutical Services is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WST Stock Analysis - Frequently Asked Questions

How have WST shares performed this year?

West Pharmaceutical Services' stock was trading at $327.56 at the beginning of the year. Since then, WST stock has decreased by 32.3% and is now trading at $221.7460.

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services, Inc. (NYSE:WST) announced its quarterly earnings data on Thursday, April, 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.23. West Pharmaceutical Services's quarterly revenue was up .4% compared to the same quarter last year.
Read the conference call transcript.

Does West Pharmaceutical Services have any subsidiaries?

West Pharmaceutical Services subsidiaries include Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., The Tech Group Inc., Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), TGPR Holdings Limited, WD SG Pte. Ltd., and others.

Who are West Pharmaceutical Services' major shareholders?

West Pharmaceutical Services' top institutional investors include First National Bank Sioux Falls (0.01%). Insiders that own company stock include Eric Mark Green, Thomas W Hofmann, Quintin J Lai, Annette F Favorite, Bernard Birkett, Cindy Reiss-Clark, Silji Abraham, Chad Winters and Charles Witherspoon.
View institutional ownership trends.

How do I buy shares of West Pharmaceutical Services?

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of West Pharmaceutical Services own?

Based on aggregate information from My MarketBeat watchlists, some other companies that West Pharmaceutical Services investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Home Depot (HD), Chevron (CVX) and Netflix (NFLX).

Company Calendar

• Last Earnings: 4/24/2025
• Record date for 5/7 Dividend: 4/30/2025
• Ex-Dividend for 5/7 Dividend: 4/30/2025
• Dividend Payable: 5/07/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 7/24/2025
• Record date for 8/6 Dividend: 7/30/2025
• Ex-Dividend for 8/6 Dividend: 7/30/2025
• Dividend Payable: 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Health Care Supplies
• Current Symbol: NYSE:WST
• CIK: 105770
• Web: www.westpharma.com
• Phone: (610) 594-2900
• Fax: 800-345-9800
• Employees: 10,600
• Year Founded: 1923

Price Target and Rating

• Average Stock Price Target: $320.00
• High Stock Price Target: $400.00
• Low Stock Price Target: $245.00
• Potential Upside/Downside: +44.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.37
• Trailing P/E Ratio: 34.81
• Forward P/E Ratio: 33.50
• P/E Growth: 5.47
• Net Income: $492.70 million
• Net Margins: 16.13%
• Pretax Margin: 19.64%
• Return on Equity: 18.23%
• Return on Assets: 13.51%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 2.77
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $2.89 billion
• Price / Sales: 5.51
• Cash Flow: $8.99 per share
• Price / Cash Flow: 24.67
• Book Value: $37.04 per share
• Price / Book: 5.99

Miscellaneous

• Outstanding Shares: 71,850,000
• Free Float: 71,464,000
• Market Cap: $15.93 billion
• Optionable: Optionable
• Beta: 1.09